Your Questions, Answered
Have questions? We’ve got you covered! Below, you’ll find answers to common questions about our product, administration, care instructions, and more. If you don’t see what you’re looking for, feel free to reach out—we’re happy to help!
What is EquiFlow?
EquiFlow is a respiratory product, derived from healthy donor horses, designed to support lung health by reducing inflammation and Exercise-Induced Pulmonary Hemorrhage (EIPH) in horses. Utilizing cutting-edge nebulized technology, EquiFlow offers a natural and innovative approach to respiratory care.
To better understand how stem cells in tendons led to the creation of EquiFlow for respiratory health, we recommend watching our informative video on our How It Works page.
Click here to view it:
EquiFlow is recommended to start with three loading doses for bleeders and two doses for horses with allergies or asthma.
What is the recommended schedule?
For Bleeders:
-
Day 1: Nebulize your horse with EquiFlow.
-
Day 8: Administer the second treatment.
-
Day 15: Complete the third and final therapy.
-
Day 22: Your horse can return to full work and competition.
To ensure the best results, plan the first treatment immediately after their last barrel run of the weekend when you have a 21-day window in your horse's schedule. Avoid lung stress during this period—light training is fine, but no strenuous activity.
For Asthma/Allergy Horses:
-
Day 1: Nebulize your horse with EquiFlow.
-
Day 8: Administer the second treatment.
-
Day 15: Your horse can return to full work and competition.
During the 15-day healing period, do not stress the lungs—light training is acceptable, but keep activity minimal to allow for proper recovery.
What side effects have been reported after using EquiFlow?
To date, over 600 horses have completed the EquiFlow field studies, and no adverse events have been reported. We have not observed any side effects such as loss of appetite, sweating, hives, increased body temperature, or colic.
EquiFlow is an allogeneic biologic, derived from healthy donor horses, with no additives, ensuring a natural and well-tolerated treatment.
Will my horse need a maintenance dose?
In most cases, yes, especially if your horse has experienced epistaxis (bleeding from the nostrils) and is returning to competition. We recommend monthly maintenance treatments to help manage this chronic condition and support long-term respiratory health.
Since EquiFlow has shown to be effective at reducing lung inflammation and mucus, horses with seasonal allergies may also benefit from monthly maintenance doses. After each treatment, we advise at least five days of rest before resuming intense activity to avoid stressing the lungs.
What is the difference between ReCellerate’s Open Label Study and the Rood & Riddle Study?
There are two separate field studies focused on EquiFlow’s effectiveness and safety:
1. ReCellerate’s Open Label Study (Launched June 2024)
-
Designed for equine bleeders and lung inflammation.
-
Horse owners will provide follow-up data post-treatment.
-
Aims to further demonstrate the safety of this no-needle alternative to Lasix.
2. Rood & Riddle 30-Horse Lung Inflammation Study
-
Conducted by Dr. Stephen Reed and Dr. Bonnie Barr at Rood & Riddle Equine Hospital.
-
Focused solely on horses with allergies, asthma, and COPD.
Each study serves a unique purpose in advancing equine respiratory health—one focusing on bleeders and inflammation, the other on allergic and chronic respiratory conditions.
Does EquiFlow help if my horse isn't a bleeder?
While it was originally developed for Thoroughbred racing bleeders. Its ability to reduce inflammation and clear mucus is currently being investigated.
Even if you haven’t seen visible blood, your horse may still experience Exercise-Induced Pulmonary Hemorrhage (EIPH). Veterinarians use a grading scale from 0 to 4 during endoscopic exams:
-
0/4: No bleeding
-
4/4: Blood visible from the nostrils (epistaxis)
-
Horses graded 1/4 or 2/4 will likely progress to higher grades over time.
In racing, 90% of horses bleed in at least one out of every three races, whether they are on Lasix or not. Each bleeding episode leads to scar tissue formation, increasing the likelihood of future episodes. EquiFlow helps manage inflammation and support long-term lung health, reducing the risk of chronic respiratory issues.
Does EquiFlow need to be refridgerated?
No, EquiFlow should never be refrigerated. If the solution is too cold, it can clog your nebulizer, preventing your horse from receiving the full benefits of the treatment.
EquiFlow is shelf-stable at room temperature for at least a year. To maintain its effectiveness, store it in a cool, dry place, away from humidity, direct sunlight, and extreme heat. Avoid exposing it to drastic temperature changes for prolonged periods.
How do I use EquiFlow?
1. Reconstitute the Solution – Add the supplied water for injection into the vial of EquiFlow. Let it sit for 1-2 minutes to fully mix.
2. Prepare the Nebulizer – Pour the brownish liquid into the medi-cup of your nebulizer.
3. Administer the Treatment – The solution will take about 10 minutes to fully nebulize and be inhaled by your horse.
EquiFlow works by strengthening capillaries, preventing them from rupturing under stress. It also reduces lung inflammation and breaks down mucus, allowing the lungs to naturally filter it out—though you won’t see mucus exiting through the mouth or nose like with other products.
Which nebulizer should I use?
Our trials were conducted exclusively with Nortev’s Flexineb, a commonly used nebulizer at racetracks. While other nebulizers may work, we can’t guarantee their effectiveness, as some models generate heat that could potentially impact certain products. We recommend using a Flexineb to ensure optimal results.
Will my horse still need Lasix if they are a bleeder?
The decision is ultimately between you and your veterinarian. However, many horse owners who have treated their bleeders with EquiFlow have successfully returned to competition without continuing Lasix. Some initially reduce the dosage—using half as much for the first weekend back—before discontinuing it altogether.
Is ReCellerate seeking investors?
Yes! ReCellerate is actively looking for investors to support an upcoming EIPH (bleeders) study proposal planned for 2025:
-
A 30-horse Thoroughbred/EIPH study at Washington State University
Investors will receive equity in ReCellerate and can choose which study their investment funds. This study will be led by Dr. Warwick Bayly (WSU) as the principal investigator.
Are you looking for distributors?
Not at this time. ReCellerate is fully focused on completing the necessary studies to obtain FDA approval and advancing research in equine respiratory health.
Do you ship to Canada?
We are no longer shipping to Canada at this time. However, we are working on establishing an Open Label Safety Study for Canada in the future.